In Part A, as of April 2017, Austria's RHI, a backward integrated refractory company is still within the midst of merging with the next biggest competitor, Brazil's Magnesita, while weighing options for future growth. Should the company pursue organic growth options and if so, which ones? Or should the company embark upon another major merger with the market leader, the UK's Vesuvius? Given anemic growth rates in the refractory industry and an aggressive consolidation plan by the Chinese government to create a global refractory giant, the newly installed CEO, Stefan Borgas, is debating the best way forward: organic growth or another major merger? In Part B, as of August 2018, the successfully merged enterprise, RHI Magnesita, is thinking through the next move on their growth path. Should the company diversify into adjacent product types such as high-temperature insulation (HTI) and/or advanced ceramics (AC)?
In September 2023, John Ridding, CEO of the Financial Times, was considering the possible impact of Generative AI on the industry and his business. Having navigated successfully the seismic shift from print to digital, and reporting record results, the company was debating how to harness the power of generative AI. The case therefore is an example of a successful business confronting a new paradigm in its market which will impact many of the industry's power and profit dynamics, making it appropriate for teaching Porter's Five Forces, S-curves, corporate innovation, sources of value and competitive advantage.
The case opens in March 2023, as Sten van der Ham and Jaap Maljers, CEO and co-founder of eBee, an electric bike (e-bike) company in Africa, are contemplating the different avenues for growth and path to profitability for the young and ambitious company. In 2023, the company had been gaining traction in Kenya under three business models and was also getting ready to raise a financing round of €8-10 million. eBee had the first mover advantage of having introduced e-bikes and van der Ham and Maljers needed to decide which levers to pull for to best grow eBee going forward. The case chronicles the founding of eBee, provides details on its bike designed for the terrain in Africa, and its unit economics. The case then lays the ground transportation Africa complete with challenges, opportunities, and the competitive outlook. The case then goes into detail about the three go-to-market channels that eBee picked to penetrate into the Kenyan market. The case goes into detail about the three different business models-vehicle as a service, fulfillment, and direct sales-that eBee is piloting in 2023 as well as providing an understanding of what each operate, their financial prospects, and growth outlooks, as eBee tries to grow its sales. While each business model presented its challenges and were yet to prove profitable at scale, van der Ham and Maljers firmly believed the in the immense opportunity to grow e-bikes in Africa and in eBee's first mover advantage. The duo was excited about geographical expansion. Others on the team and advisory board held that, obtaining proof of concept in Kenya first would be more helpful, while some suggested to eliminate some of the business models and focus more on others.
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis - one of the largest pharmaceutical companies in the world - is, among other ventures, discovering, developing, and marketing patent-protected prescription medicines, as well as addressing unmet medical needs and diseases for which no effective treatments or cures exist. In late 2011, Novartis executives became aware of a revolutionary treatment technology developed by researchers at the University of Pennsylvania (UPenn). This technology was designed as a one-time, personalized drug to cure certain types of cancers such as lymphomas and leukemia. Section Chief of Cellular Therapy and Transplant at the Children's Hospital of Philadelphia Stephan A. Grupp, MD, Ph.D. commented on the innovation as follows: "I've been an oncologist for 20 years, and I have never, ever seen anything like this." After approaching UPenn scientists, Novartis decided to develop and commercialize this technology as the company possessed the relevant capabilities. This case series then explores the introduction and scaling of this new treatment over three parts. Case A describes the various challenges Joe Jimenez, the then CEO of Novartis, faced during the launch of the new treatment in 2016. Case B (separate) focuses on the persistent problems with drug manufacturing and scaling this part of the business model design after its launch in 2017. Lastly, case C (separate) examines how Novartis solved the persistent problems and envisioned the future in this new, inspiring area of medicine.
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis - one of the largest pharmaceutical companies in the world - is, among other ventures, discovering, developing, and marketing patent-protected prescription medicines, as well as addressing unmet medical needs and diseases for which no effective treatments or cures exist. In late 2011, Novartis executives became aware of a revolutionary treatment technology developed by researchers at the University of Pennsylvania (UPenn). This technology was designed as a one-time, personalized drug to cure certain types of cancers such as lymphomas and leukemia. Section Chief of Cellular Therapy and Transplant at the Children's Hospital of Philadelphia Stephan A. Grupp, MD, Ph.D. commented on the innovation as follows: "I've been an oncologist for 20 years, and I have never, ever seen anything like this." After approaching UPenn scientists, Novartis decided to develop and commercialize this technology as the company possessed the relevant capabilities. This case series then explores the introduction and scaling of this new treatment over three parts. Case A describes the various challenges Joe Jimenez, the then CEO of Novartis, faced during the launch of the new treatment in 2016. Case B (separate) focuses on the persistent problems with drug manufacturing and scaling this part of the business model design after its launch in 2017. Lastly, case C (separate) examines how Novartis solved the persistent problems and envisioned the future in this new, inspiring area of medicine.
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis - one of the largest pharmaceutical companies in the world - is, among other ventures, discovering, developing, and marketing patent-protected prescription medicines, as well as addressing unmet medical needs and diseases for which no effective treatments or cures exist. In late 2011, Novartis executives became aware of a revolutionary treatment technology developed by researchers at the University of Pennsylvania (UPenn). This technology was designed as a one-time, personalized drug to cure certain types of cancers such as lymphomas and leukemia. Section Chief of Cellular Therapy and Transplant at the Children's Hospital of Philadelphia Stephan A. Grupp, MD, Ph.D. commented on the innovation as follows: "I've been an oncologist for 20 years, and I have never, ever seen anything like this." After approaching UPenn scientists, Novartis decided to develop and commercialize this technology as the company possessed the relevant capabilities. This case series then explores the introduction and scaling of this new treatment over three parts. Case A describes the various challenges Joe Jimenez, the then CEO of Novartis, faced during the launch of the new treatment in 2016. Case B (separate) focuses on the persistent problems with drug manufacturing and scaling this part of the business model design after its launch in 2017. Lastly, case C (separate) examines how Novartis solved the persistent problems and envisioned the future in this new, inspiring area of medicine.
Founded in 2010, in just one decade, the Swiss company On had established itself as a main player in global sports footwear and apparel. Based on an unconventional strategy which one of the founders labeled as "obsessively distinct," On grew its sales with a compound annual growth rate of more than 75% between 2013 and 2021, and went public in 2021. In 2022, On was on the verge of launching a revolutionary new subscription-based service that exclusively provided customers with the Cloudneo, a fully recyclable performance running shoe. Designed as a circular business model, Cyclon would deviate from On's proven growth strategy and would contradict the dominant logic of how running shoes were consumed. On had to decide whether or not to implement the subscription-based business model as envisioned.